Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Just a thought
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Apr 21, 2021 11:46am
143 Views
Post# 33037251

RE:RE:RE:RE:RE:RE:RE:RE:Just a thought

RE:RE:RE:RE:RE:RE:RE:RE:Just a thought
bigmack1 wrote: This is exactly how this thing could play out. Nicely out Mugs..
How many retailers do you think are lurking about? Out of curiosity. 


Sorry Bigmack - if you're asking about how many Big Pharma players ... I'd guess 2 or 3 right now ... paying close attention and maybe having initial chats with ATE.  I'm sure there are others to join but I really don't know.  

------

Let me put it this way, I had a really cool new technology for the education industry.  I called each textbook publisher and within a week, they all wanted to meet with us - without hesitation - after seeing the demo.  There is too much money to be lost if you don't keep an eye on developments and if you don't entertain the developers. 

Acquisitions is the name of the game - especially in pharma.

So ... I don't think ATE will have an issue getting to the table with any Big Pharma that they want.  It may not lead to a deal ... but ... Big Pharm will listen and they will investigate how they can fit into the bigger picture of H2S.

IMO.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities